The effect of disease modifying therapies on CD62L expression in multiple sclerosis [0.03%]
疾病修正治疗对多发性硬化病CD62L表达的影响
Margarete Maria Voortman,Paul Greiner,Daniel Moser et al.
Margarete Maria Voortman et al.
Background: The increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasati...
Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders [0.03%]
AQP4-IgG阳性及MOG-IgG阳性视神经脊髓炎谱系障碍的疼痛症状
Susanna Asseyer,Felix Schmidt,Claudia Chien et al.
Susanna Asseyer et al.
Background: Pain is a frequent symptom in aquaporin-4-immunoglobulin-G-positive neuromyelitis optica spectrum disorders (AQP4-IgG-pos. NMOSD). Data on pain in myelin-oligodendrocyte-glycoprotein-immunoglobulin-G autoimmun...
Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis [0.03%]
参考视频可减少多发性硬化症运动障碍评估的变异性
Marcus D&#x;Souza,Saskia Steinheimer,Jonas Dorn et al.
Marcus D&#x;Souza et al.
Motor dysfunction, particularly ataxia, is one of the predominant clinical manifestations in patients with multiple sclerosis (MS). Assessment of motor dysfunction suffers from a high variability. We investigated whether the clinical rating...
Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis [0.03%]
视神经脊髓炎谱系疾病和多发性硬化视神经炎临床特征的差异分析
Jindapa Srikajon,Sasitorn Siritho,Chanon Ngamsombat et al.
Jindapa Srikajon et al.
Background: Optic neuritis (ON) is one of the common manifestations both in neuromyelitis-optica spectrum disorders (NMOSD) and in multiple sclerosis (MS). ...
U Rot,Å Sandelius,A Emeršič et al.
U Rot et al.
Background/objective: Novel biomarkers identifying and predicting disease activity in multiple sclerosis (MS) would be valuable for primary diagnosis and as outcome measures for monitoring therapeutic effects in clinical ...
Promotion of physical activity and exercise in multiple sclerosis: Importance of behavioral science and theory [0.03%]
行为科学和理论在促进多发性硬化症患者进行身体活动和锻炼中的作用
Robert W Motl,Dorothy Pekmezi,Brooks C Wingo
Robert W Motl
There is an obvious disconnect between evidence of benefits and rates of participation in exercise and physical activity among people living with multiple sclerosis (MS). We propose that the problem with exercise behavior in MS (i.e. lack o...
Objective and subjective measures of dalfampridine efficacy in clinical practice [0.03%]
临床实践中用于评价二甲福明疗效的客观及主观测定方法
Sylvia Klineova,Rebecca Farber,Joshua Friedman et al.
Sylvia Klineova et al.
Background: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and...
Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden [0.03%]
一项基于瑞典多发性硬化症登记处的研究：残疾程度不同的人的费用和生活质量
Hanna Gyllensten,Andrius Kavaliunas,Kristina Alexanderson et al.
Hanna Gyllensten et al.
Background: Population-based estimates of costs of illness and health-related quality of life, by disability levels among people with multiple sclerosis, are lacking. ...
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? [0.03%]
克拉利din：在资源匮乏地区用于多发性硬化症的标外疾病修正疗法？
Zhifeng Mao,César Álvarez-Gonzalez,Stefania De Trane et al.
Zhifeng Mao et al.
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. ...
Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study [0.03%]
一种补充12项多发性硬化行走量表的步态模块的发展：一种混合方法的研究
Sara Strzok,Sophie Cleanthous,Farrah Pompilus et al.
Sara Strzok et al.
Background and objective: The 12-item Multiple Sclerosis Walking Scale (MSWS-12) is a patient-reported outcome instrument that quantifies the progressive loss of walking ability from the patient perspective. However, prev...